Sanjeev Mariathasan Selected Research

atezolizumab

1/2022	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.
1/2022	Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
1/2021	Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
1/2021	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
1/2021	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
1/2021	ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
1/2020	High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
1/2020	Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer.
1/2020	Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
1/2020	Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sanjeev Mariathasan Research Topics

Disease

19	Neoplasms (Cancer) 01/2022 - 05/2016
10	Carcinoma (Carcinomatosis) 01/2021 - 05/2016
4	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 12/2018
4	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2020
4	Infections 10/2018 - 01/2007
3	Disease Progression 01/2022 - 01/2020
3	Inflammation (Inflammations) 01/2020 - 01/2007
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2019
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 01/2020
1	Pyelonephritis 01/2021
1	Urinary Tract Infections (Urinary Tract Infection) 01/2021
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2021
1	Genetic Risk Score 01/2020
1	Vitiligo 01/2020
1	Atopic Dermatitis (Atopic Eczema) 01/2020
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2020
1	Neoplasm Metastasis (Metastasis) 01/2018
1	Staphylococcal Infections 01/2017
1	Bacterial Infections (Bacterial Infection) 01/2017
1	Pneumonia (Pneumonitis) 05/2016
1	Exanthema (Rash) 05/2016
1	Arthritis (Polyarthritis) 07/2014
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/2010
1	Anthrax 06/2008
1	Legionnaires' Disease (Legionnaire's Disease) 03/2006
1	Shock 07/2004

Drug/Important Bio-Agent (IBA)

17	atezolizumabIBA 01/2022 - 05/2016
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2016
5	Immune Checkpoint InhibitorsIBA 01/2022 - 05/2016
4	LigandsIBA 01/2021 - 01/2018
3	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 01/2017
3	Hormones (Hormone)IBA 01/2022 - 01/2020
3	PlatinumIBA 01/2020 - 05/2016
3	AntibodiesIBA 01/2020 - 01/2017
2	Interleukin-8 (Interleukin 8)IBA 03/2021 - 01/2020
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2020
2	B7-H1 AntigenIBA 01/2021 - 01/2017
2	Anti-Bacterial Agents (Antibiotics)IBA 10/2018 - 01/2017
2	CytokinesIBA 07/2014 - 07/2010
1	TensinsIBA 01/2022
1	abirateroneIBA 01/2022
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2022
1	enzalutamideIBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2021
1	Sunitinib (Sutent)FDA Link 12/2020
1	Bevacizumab (Avastin)FDA Link 12/2020
1	Immunoglobulins (Immunoglobulin)IBA 01/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020
1	AndrogensIBA 01/2020
1	Tumor Biomarkers (Tumor Markers)IBA 11/2019
1	Coloring Agents (Dyes)IBA 01/2019
1	AminopeptidasesIBA 12/2018
1	Surface Antigens (Surface Antigen)IBA 10/2018
1	CollagenIBA 01/2018
1	Docetaxel (Taxotere)FDA Link 01/2018
1	vinflunineIBA 01/2018
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2018
1	Taxoids (Taxanes)IBA 01/2018
1	Therapeutic UsesIBA 01/2017
1	AntigensIBA 11/2016
1	Alanine Transaminase (SGPT)IBA 05/2016
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 05/2016
1	Vancomycin FDA LinkGeneric 11/2015
1	Interleukin-15 (Interleukin 15)IBA 07/2010
1	AutoantigensIBA 07/2010
1	Acetylmuramyl-Alanyl-IsoglutamineIBA 06/2008
1	InflammasomesIBA 01/2007
1	Pattern Recognition ReceptorsIBA 03/2006
1	LipopolysaccharidesIBA 07/2004
1	Interleukin-18 (Interleukin 18)IBA 07/2004

Therapy/Procedure

6	Immunotherapy 01/2022 - 12/2018
6	Drug Therapy (Chemotherapy) 01/2021 - 05/2016
4	Castration 01/2022 - 01/2020
4	Therapeutics 01/2021 - 12/2018
3	Cystectomy 01/2022 - 11/2019
1	Nephroureterectomy 01/2021
1	Lymph Node Excision (Lymph Node Dissection) 01/2021
1	Aftercare (After-Treatment) 11/2019